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Abstract: We have made the novel observations that mice lacking the Jak 
tyrosine kinase member Tyk2 become progressively obese due to aberrant 
development of  Myf5+ brown adipose tissue (BAT). Tyk2 RNA levels in BAT 
and skeletal muscle, which shares a common progenitor with BAT, are 
dramatically decreased in mice placed on a high fat diet and in obese 
humans. Expression of Tyk2 or the constitutively active form of the 
transcription factor Stat3 (CAStat3) restores differentiation in Tyk2-/- 
preadipocytes. Furthermore, Tyk2-/- mice expressing CAStat3 transgene in 
BAT also show improved BAT development, normal levels of insulin and 
significantly lower body weights. Stat3 binds to PRDM16, a master 
regulator of BAT differentiation, and enhances the stability of PRDM16 
protein. These results define novel roles for Tyk2 and Stat3 as critical 
determinants of brown fat-lineage and suggest that altered levels of Tyk2 
are associated with obesity in both rodents and humans. 
 
Suggested Reviewers:  
 
Opposed Reviewers:  
 
 
Dear Granger: 
 
I appreciate the opportunity to submit a revised manuscript to Cell Metabolism 
entitled: “Tyk2 and Stat3 Regulate Brown Adipose Tissue Differentiation and 
Obesity”. We have modified the manuscript to include most of the experiments the 
reviewers suggested. Below I have addressed the reviewer’s concerns. 
 
Sincerely, 
 
Andrew Larner 
 
 
Reviewers' Comments: 
 
 
Reviewer #1: In a manuscript entitled: "Tyk2 and Stat3 Regulate Brown Adipose Tissue 
Differentiation and Obesity" Derecka et al. discuss the role of Tyk 2 and Stat3. In general 
this is an excellent manuscript, the experiments are relevant and carefully executed with 
the necessary controls. The findings are interesting and important. This reviewer only has 
a few comments: 
 
The author states that skeletal muscle cells and BAT "originate from the same Myf5 
positive progenitor cells, ." the authors should make clear that two different populations of 
BAT cells exist: the so cold "beige/brite" cells as well as the interscapular or classical 
BAT cells (e.g. Wu J. et al. Cell 2012 Jul 10). Only classical BAT originates form Myf5 
positive precursors whereas beige BAT cells are derived form a different cell population. 
Even though this is briefly mentioned in the "Discussion" section it should be pointed out 
already in the abstract. Moreover, it would be of interest to examine whether or not the 
changes in classical BAT cells described in the ms also are present in beige BAT cells. 
We have added a comment in the abstract clarifying our studies were performed in 
Myf5+ brown adipocytes. We are presently exploring the role of Tyk2 expression in 
Myf5-negative beige cells. Thus far the results have been inconclusive. The 
variability in these results may be due to the recently published observation that 
there are both Myf5+ and Myf5- brown adipocytes in WAT (Sanchez-Gurmaches et al., 
2012).   
 
The phenotype observed includes alteration in mRNA levels of genes like ucp1 and a few 
others as depicted in figures 1F, 4A, 1I. The authors should make sure that the changes 
in mRNA levels also are reflected by changes in corresponding protein levels using 
Western blots. Fortunately good commercial antibodies are available for these proteins. 
The revised version contains western blots that were used to measure 
concentrations of proteins depicted in figures 1F and 4A, except PGC1. We have 
not located a good commercial antibody that recognizes mouse PGC1 We 
observed no increase  in levels of UCP1 in Tyk2+/+ BAT with cold exposure (Fig. 1I 
in previous version and 1J in the revised version). However, changes in the levels 
Cover Letter
of the protein have been reported to require more than 12 hours exposure to cold 
(Jacobsson et al., 1994; Klingenspor, 2003). 
 
Fig. 1D shows that in response to high-fat diet Tyk2 mRNA levels are lowered in BAT and 
SKM whereas no changes could be detected in WAT and liver. The authors should show 
protein and activity data for Tyk2. 
The revised manuscript shows the protein levels of Tyk2 on a normal chow and 
HFD in BAT and percent decrease of Tyk2 protein in SKM. 
 
Since Tyk2 is regulated in a similar way in both skeletal muscle and iBAT would it be 
possible that some of the phenotypes observed derive form dysfunction of skeletal 
muscle cells? Or even a combined general malfunction of mitochondria in SKM and 
iBAT? This possibility should be discussed more clearly in the ms.  
This is an important issue which has been addressed in the discussion in the 
revised manuscript. 
 
In fig S3B opa1, mfn1 and mfn2 mRNA levels are shown to be lower in Tyk2 -/- mice as 
compared with wt. This is accompanied with a obese/dysmetabolic phenotype the 
authors should point out that the reverse i.e. induced levels of opa1, mfn1 and mfn2 has 
been associated with a "healthy" lean insulin sensitive phenotype, please see Lidell M.E. 
et al. Diabetes 60:427-35, 2011. 
A reference to this paper is in the revised manuscript. 
 
 
Reviewer #2: This is an interesting study that provides novel insights into the 
development of brown adipose tissue. The data show an important role for Tyk2 and 
STAT3 in regulating early events in brown adipocyte formation. Loss of Tyk2 leads to 
obesity and insulin resistance in mice due most likely to defective BAT activity. These 
data will be of interest to the readership of Cell Metabolism and will contribute 
significantly to our understanding of BAT development and the role BAT plays in overall 
metabolic homeostasis. 
 
 
 
Reviewer #3: The manuscript by Derecka et al clearly indicates that global congenital 
deficiency of Tyk2 results in obesity and some characteristics of diabetes. The results 
suggest a potential role for Tyk2 in the adipogenesis of brown precursor cells that can be 
rescued with CASTAT3. There is also data to show an association of PRDM16 and 
STAT3 that clearly merits further study.   
 
Comments for consideration 
 
The majority of studies indicate that Tyk2 has limited tissue distribution compared to 
JAKs 1 and 2. What are the levels of Tyk2 in BAT and skeletal muscle (SM) compared to 
cells where this protein is known to be highly expressed? Are the levels of Tyk2 
equivalent in BAT and SM as indicated in Fig. 1D. 
Tyk2 is ubiquitously expressed (Strobl et al., 2011). We have included a western 
blot showing the levels of the protein in a variety of tissues including SKM, WAT 
and BAT (Supplemental Fig. S2A). The levels of the protein are increased in BAT 
compared with SKM. 
 
A limitation to this study is the knockout is global and congenital. The observed metabolic 
effects could be a result of developmental events. At the least, this issue should be 
considered in the discussion. 
We have commented on this issue in the discussion. 
 
Many references in the text are numerical, but the reference section is by author last 
name. Hence, it is very difficult to determine source of some information. What is the 
evidence that tyk2 is the nucleus of BAT?  
We have corrected the problem with the references. There is no direct evidence 
that Tyk2 is in the nucleus of BAT. The report indicating that Tyk2 is in the nucleus 
used HT1080 cells, which were derived from a human sarcoma. Jak2 was also 
reported to be in the nucleus in hematopoietic cell lines as well as primary CD34+ 
stem cells.  
 
What tyk2 and/or STAT3 activators mediate the regulation of key BAT genes like UCP-1 
and cidea?  
The mediators of Tyk2 need to be delineated. Two possibilities are that Tyk2 
phosphorylates Stat3 and other TFs associated with BAT differentiation. However, 
we have no evidence that Stat3 directly mediates the transcription of BAT-selective 
genes such as UCP1.  Alternatively, Tyk2 may directly or indirectly participate in 
epigenetic modifications of chromatin involved in expression of BAT-selective 
genes. 
 
The relevance of the data in Figures 3C and 3D is not clear in the absence of additional 
studies.  An interesting question is whether an interaction of STAT3 and PRDM16 is 
effected by TZDs. The lack of rosi induced PRDM16 expression is likely because these 
cells are preadipocytes and do not have any PPARg.  The levels of PPARg protein 
should be shown for the studies in Figures 3C and 3D.  
The interaction between Stat3 and PRDM16 is not affected by TZDs. The levels of 
PPAR protein are not altered between Stat3+/+ and Stat3-/- (with or without 
rosiglitazone treatment). Also the induction of PPAR upon rosiglitazone treatment 
in preadipocytes is equal between both cell types. This information has been 
included in the revised Fig. 3E and 3F. 
 
An association of STAT3 and PRDM16 should also be demonstrated by performing the 
IP with STAT3. Where in the cell is this interaction taking place? Can this interaction be 
shown without retroviral ectopic expression of PRDM16? 
The revised Fig. 3C demonstrates that antibodies to Stat3 immunoprecipitate 
PRDM16.  We also observe the interaction in adipocytes which express 
endogenous levels of PRDM16 (Fig. 3D). Using extracts prepared from isolated 
nuclei we have been able to detect an association between Stat3 and PRDM16 
(data not shown).  
 
Does Tyk2 activate other STATs besides STAT3? If so, could another STAT also rescue 
the tyk2 deficiency? 
Cytokines that activate Tyk2 also primarily activate Stat3. However, other Stats 
under selective circumstances can also be activated by Tyk2. We believe it is 
unlikely that other Stats could rescue the Tyk2 deficiency because, when Stat3 
expression is disrupted by shRNA in wild type preadipocytes, these cells do not 
acquire a brown adipocyte phenotype. These preadipocytes contain all the Stats 
and Tyk2, which are ubiquitously expressed. If another Stat could replace Stat3, 
then the preadipocytes should differentiate into functional brown adipocytes  
 
An examination of Tyk2 expression and/or activation in human obesity/T2DM would 
strengthen the study. In fact, the Materials section describes human subjects, but the 
data is not in the paper.  
The data concerning Tyk2 expression in obese humans is presented in Fig. 1E and 
supplemental Fig. S2F 
 
The aP2 are no longer considered a strong model for adipocyte expression since aP2 
can be expressed in macrophages and the brain. The expression of aP2 in this particular 
mouse requires investigation. 
Unfortunately, the analysis of the CAStat3 transgenic mice was initiated prior to 
the availability of the adiponectin Cre, which expresses in both WAT and BAT. 
Although the adiponectin Cre has its advantages, the fact that the aP2 Cre 
randomly expresses in only BAT or WAT has allowed us to exclude the role of 
WAT in the actions of CAStat3. We have examined bone marrow macrophages 
from mice that express aP2 Cre and CAStat3 and have not detected expression of 
CAStat3 in these macrophages. It is possible that CAStat3 is also expressed in the 
brains of these mice. Assuming mice which express CAStat3 in WAT, also express 
CAStat3 in brain, one would expect these animals to have a more normal metabolic 
phenotype than Tyk2-/- mice, if expression of CAStat3 in the brain was contributing 
to the phenotype. We observe no change in the development of obesity in mice 
that express CAStat3 in WAT (data not shown). This issue has been addressed in 
the discussion of the revised manuscript.  
 
The results indicating "The observation that rosiglitazone-induced stabilization of 
PRDM16 protein is absent in Stat3-/- brown preadipocytes under conditions where there 
is no change in levels of PRDM16 RNA suggests a new mechanism of Stat3 action' are 
over interpreted. First, the levels of PPARg are not considered. Secondly, the authors did 
not examine stabilization of PRDM16; they only examined steady state levels. . 
We have modified the original figure (3C and 3D) to include the levels of PPAR in 
these immunoblots. We have examined whether the expression of Stat3 controls 
the rate of degradation of PRDM16 by treating cells with cycloheximide as 
described by Ohno et al (Ohno et al., 2012). There were no changes in the half-life 
of PRDM16 protein in Stat3-/- compared to Stat3+/+ adipocytes, suggesting that in 
these cells the rate of translation of PRDM16 is being influenced by the expression 
of Stat3. However, these results are difficult to interpret because the endogenous 
levels of PRDM16 are very low in Stat3-/- cells, which makes difficult to analyze the 
rates of decay of the protein. 
 
Minor Points: 
 
The data is not published yet, but there is convincing evidence from David Guertin's 
laboratory that was presented at the ADA meeting that the precursors for BAT and SM is 
also found in other tissues. Overall, the data indicated that MYRF5 can not be assumed 
to be a precursor just for BAT and SM. Considering this upcoming data and evident 
similar observations by other labs, the authors may want to consider rewording some 
section that indicate 'BAT and skeletal muscle, which shares a common progenitor with 
BAT." and "Since BAT and skeletal muscles originate from the same Myf5 positive 
progenitor cells, (8) we conclude that Tyk2 kinase may be important at an early stage of 
development of these progenitors".  
The findings of Guertin’s lab have been included in the discussion. 
 
The westerns should contain MW indicators 
MW markers are routinely run on SDS page gels, but are not included in the 
figures. 
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Response to  Reviewers' Comments: 
 
 
Reviewer #1: In a manuscript entitled: "Tyk2 and Stat3 Regulate Brown Adipose Tissue 
Differentiation and Obesity" Derecka et al. discuss the role of Tyk 2 and Stat3. In general 
this is an excellent manuscript, the experiments are relevant and carefully executed with 
the necessary controls. The findings are interesting and important. This reviewer only has 
a few comments: 
 
The author states that skeletal muscle cells and BAT "originate from the same Myf5 
positive progenitor cells, ." the authors should make clear that two different populations of 
BAT cells exist: the so cold "beige/brite" cells as well as the interscapular or classical 
BAT cells (e.g. Wu J. et al. Cell 2012 Jul 10). Only classical BAT originates form Myf5 
positive precursors whereas beige BAT cells are derived form a different cell population. 
Even though this is briefly mentioned in the "Discussion" section it should be pointed out 
already in the abstract. Moreover, it would be of interest to examine whether or not the 
changes in classical BAT cells described in the ms also are present in beige BAT cells. 
We have added a comment in the abstract clarifying our studies were performed in 
myf5+ brown adipocytes. We are presently exploring the role of Tyk2 expression in 
myf5-negative beige cells. Thus far the results have been inconclusive. The 
variability in these results may be due to the recently published observation that 
there are both myf5+ and myf5- brown adipocytes in WAT (Sanchez-Gurmaches et al., 
2012).   
 
The phenotype observed includes alteration in mRNA levels of genes like ucp1 and a few 
others as depicted in figures 1F, 4A, 1I. The authors should make sure that the changes 
in mRNA levels also are reflected by changes in corresponding protein levels using 
Western blots. Fortunately good commercial antibodies are available for these proteins. 
The revised version contains western blots that were used to measure 
concentrations of proteins depicted in figures 1F and 4A, except PGC1α. We have 
not located a good commercial antibody that recognizes mouse PGC1α .  We 
observed no increase  in levels of UCP1 in Tyk2+/+ BAT with cold exposure (Fig. 1I 
in previous version and 1J in the revised version). However, changes in the levels 
of the protein have been reported to require more than 12 hours exposure to cold 
(Jacobsson et al., 1994; Klingenspor, 2003). 
 
Fig. 1D shows that in response to high-fat diet Tyk2 mRNA levels are lowered in BAT and 
SKM whereas no changes could be detected in WAT and liver. The authors should show 
protein and activity data for Tyk2. 
The revised manuscript shows the protein levels of Tyk2 on a normal chow and 
HFD in BAT and percent decrease of Tyk2 protein in SKM. 
 
Since Tyk2 is regulated in a similar way in both skeletal muscle and iBAT would it be 
possible that some of the phenotypes observed derive form dysfunction of skeletal 
muscle cells? Or even a combined general malfunction of mitochondria in SKM and 
iBAT? This possibility should be discussed more clearly in the ms.  
This is an important issue which has been addressed in the discussion in the 
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revised manuscript. 
 
In fig S3B opa1, mfn1 and mfn2 mRNA levels are shown to be lower in Tyk2 -/- mice as 
compared with wt. This is accompanied with a obese/dysmetabolic phenotype the 
authors should point out that the reverse i.e. induced levels of opa1, mfn1 and mfn2 has 
been associated with a "healthy" lean insulin sensitive phenotype, please see Lidell M.E. 
et al. Diabetes 60:427-35, 2011. 
A reference to this paper is in the revised manuscript. 
 
 
Reviewer #2: This is an interesting study that provides novel insights into the 
development of brown adipose tissue. The data show an important role for Tyk2 and 
STAT3 in regulating early events in brown adipocyte formation. Loss of Tyk2 leads to 
obesity and insulin resistance in mice due most likely to defective BAT activity. These 
data will be of interest to the readership of Cell Metabolism and will contribute 
significantly to our understanding of BAT development and the role BAT plays in overall 
metabolic homeostasis. 
 
 
 
Reviewer #3: The manuscript by Derecka et al clearly indicates that global congenital 
deficiency of Tyk2 results in obesity and some characteristics of diabetes. The results 
suggest a potential role for Tyk2 in the adipogenesis of brown precursor cells that can be 
rescued with CASTAT3. There is also data to show an association of PRDM16 and 
STAT3 that clearly merits further study.   
 
Comments for consideration 
 
The majority of studies indicate that Tyk2 has limited tissue distribution compared to 
JAKs 1 and 2. What are the levels of Tyk2 in BAT and skeletal muscle (SM) compared to 
cells where this protein is known to be highly expressed? Are the levels of Tyk2 
equivalent in BAT and SM as indicated in Fig. 1D. 
Tyk2 is ubiquitously expressed (Strobl et al., 2011). We have included a western 
blot showing the levels of the protein in a variety of tissues including SKM, WAT 
and BAT (Supplemental Fig. S2A). The levels of the protein are increased in BAT 
compared with SKM. 
 
A limitation to this study is the knockout is global and congenital. The observed metabolic 
effects could be a result of developmental events. At the least, this issue should be 
considered in the discussion. 
We have commented on this issue in the discussion. 
 
Many references in the text are numerical, but the reference section is by author last 
name. Hence, it is very difficult to determine source of some information. What is the 
evidence that tyk2 is the nucleus of BAT?  
We have corrected the problem with the references. There is no direct evidence 
that Tyk2 is in the nucleus of BAT. The report indicating that Tyk2 is in the nucleus 
used HT1080 cells which were derived from a human sarcoma. Jak2 was also 
reported to be in the nucleus in hematopoietic cell lines as well as primary CD34+ 
stem cells.  
 
What tyk2 and/or STAT3 activators mediate the regulation of key BAT genes like UCP-1 
and cidea?  
The mediators of Tyk2 need to be delineated. Two possibilities are that Tyk2 
phosphorylates Stat3 and other TFs associated with BAT differentiation. However, 
we have no evidence that Stat3 directly mediates the transcription of BAT-selective 
genes such as UCP1.  Alternatively, Tyk2 may directly or indirectly participate in 
epigenetic modifications of chromatin involved in expression of BAT-selective 
genes. 
 
The relevance of the data in Figures 3C and 3D is not clear in the absence of additional 
studies.  An interesting question is whether an interaction of STAT3 and PRDM16 is 
effected by TZDs. The lack of rosi induced PRDM16 expression is likely because these 
cells are preadipocytes and do not have any PPARg.  The levels of PPARg protein 
should be shown for the studies in Figures 3C and 3D.  
The interaction between Stat3 and PRDM16 is not affected by TZDs. The levels of 
PPARγ  protein are not altered between Stat3+/+ and Stat3-/- (with or without 
rosiglitazone treatment). Also the induction of PPARγ  upon rosiglitazone treatment 
in preadipocytes is equal between both cell types. This information has been 
included in the revised Fig. 3E and 3F. 
 
An association of STAT3 and PRDM16 should also be demonstrated by performing the 
IP with STAT3. Where in the cell is this interaction taking place? Can this interaction be 
shown without retroviral ectopic expression of PRDM16? 
The revised Fig. 3C demonstrates that antibodies to Stat3 immunoprecipitate 
PRDM16.  We also observe the interaction in adipocytes which express 
endogenous levels of PRDM16 (Fig. 3D). Using extracts prepared from isolated 
nuclei we have been able to detect an association between Stat3 and PRDM16 
(data not shown).  
 
Does Tyk2 activate other STATs besides STAT3? If so, could another STAT also rescue 
the tyk2 deficiency? 
Cytokines that activate Tyk2 also primarily activate Stat3. However, other Stats 
under selective circumstances can also be activated by Tyk2. We believe it is 
unlikely that other Stats could rescue the Tyk2 deficiency because, when Stat3 
expression is disrupted by shRNA in wild type preadipocytes, these cells do not 
acquire a brown adipocyte phenotype. These preadipocytes contain all the Stats 
and Tyk2, which are ubiquitously expressed. If another Stat could replace Stat3, 
then the preadipocytes should differentiate into functional brown adipocytes  
 
An examination of Tyk2 expression and/or activation in human obesity/T2DM would 
strengthen the study. In fact, the Materials section describes human subjects, but the 
data is not in the paper.  
The data concerning Tyk2 expression in obese humans is presented in Fig. 1E and 
supplemental Fig. S2F 
 
The aP2 are no longer considered a strong model for adipocyte expression since aP2 
can be expressed in macrophages and the brain. The expression of aP2 in this particular 
mouse requires investigation. 
Unfortunately, the analysis of the CAStat3 transgenic mice was initiated prior to 
the availability of the adiponectin Cre, which expresses in both WAT and BAT. 
Although the adiponectin Cre has its advantages, the fact that the aP2 Cre 
randomly expresses in only BAT or WAT has allowed us to exclude the role of 
WAT in the actions of CAStat3. We have examined bone marrow macrophages 
from mice that express aP2 Cre and CAStat3 and have not detected expression of 
CAStat3 in these macrophages. It is possible that CAStat3 is also expressed in the 
brains of these mice. Assuming mice which express CAStat3 in WAT, also express 
CAStat3 in brain, one would expect these animals to have a more normal metabolic 
phenotype than Tyk2-/- mice, if expression of CAStat3 in the brain was contributing 
to the phenotype. We observe no change in the development of obesity in mice 
that express CAStat3 in WAT (data not shown). This issue has been addressed in 
the discussion of the revised manuscript.  
 
The results indicating "The observation that rosiglitazone-induced stabilization of 
PRDM16 protein is absent in Stat3-/- brown preadipocytes under conditions where there 
is no change in levels of PRDM16 RNA suggests a new mechanism of Stat3 action' are 
over interpreted. First, the levels of PPARg are not considered. Secondly, the authors did 
not examine stabilization of PRDM16; they only examined steady state levels. . 
We have modified the original figure (3C and 3D) to include the levels of PPARγ  in 
these immunoblots. We have examined whether the expression of Stat3 controls 
the rate of degradation of PRDM16 by treating cells with cycloheximide as 
described by Ohno et al (Ohno et al., 2012). There were no changes in the half-life 
of PRDM16 protein in Stat3-/- compared to Stat3+/+ adipocytes, suggesting that in 
these cells the rate of translation of PRDM16 is being influenced by the expression 
of Stat3. However, these results are difficult to interpret because the endogenous 
levels of PRDM16 are very low in Stat3-/- cells, which makes difficult to analyze the 
rates of decay of the protein. 
 
Minor Points: 
 
The data is not published yet, but there is convincing evidence from David Guertin's 
laboratory that was presented at the ADA meeting that the precursors for BAT and SM is 
also found in other tissues. Overall, the data indicated that MYRF5 can not be assumed 
to be a precursor just for BAT and SM. Considering this upcoming data and evident 
similar observations by other labs, the authors may want to consider rewording some 
section that indicate 'BAT and skeletal muscle, which shares a common progenitor with 
BAT." and "Since BAT and skeletal muscles originate from the same Myf5 positive 
progenitor cells, (8) we conclude that Tyk2 kinase may be important at an early stage of 
development of these progenitors".  
The findings of Guertin’s lab have been included in the discussion. 
 
The westerns should contain MW indicators 
MW markers are routinely run on SDS page gels, but are not included in the 
figures. 
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Abstract 
   
We have made the novel observations that mice lacking the Jak tyrosine kinase 
member Tyk2 become progressively obese due to aberrant development of  Myf5+ brown 
adipose tissue (BAT). Tyk2 RNA levels in BAT and skeletal muscle, which shares a common 
progenitor with BAT, are dramatically decreased in mice placed on a high fat diet and in 
obese humans. Expression of Tyk2 or the constitutively active form of the transcription factor 
Stat3 (CAStat3) restores differentiation in Tyk2-/- brown preadipocytes. Furthermore, Tyk2-/- 
mice expressing CAStat3 transgene in BAT also show improved BAT development, normal 
levels of insulin and significantly lower body weights. Stat3 binds to PRDM16, a master 
regulator of BAT differentiation, and enhances the stability of PRDM16 protein. These results 
define novel roles for Tyk2 and Stat3 as critical determinants of brown fat-lineage and 
suggest that altered levels of Tyk2 are associated with obesity in both rodents and humans. 
 
Introduction  
 Obesity occurs when caloric intake exceeds energy expenditure with excess nutrients 
stored as fat. There are two functionally different types of fat: white adipose tissue (WAT) 
and brown adipose tissue (BAT). WAT is the primary site of energy storage and also 
synthesizes and releases a variety of cytokines and hormones that modulate the actions of 
insulin. Obesity results from excessive accumulation of WAT. In contrast to WAT, BAT is 
responsible for energy expenditure in the form of thermogenesis. Uncoupling protein-1 (UCP-
1) is expressed only in BAT and uncouples oxidative phosphorylation from ATP generation, 
resulting in the production of heat instead of ATP. BAT deposits are present in all mammals, 
but in humans these deposits were believed to be  nonfunctional except in newborns. 
However, over the past 4 years it has become evident that BAT has an important role in 
human adults in the regulation of energy expenditure (Cypess et al., 2009; Nedergaard et al., 
2007; Saito et al., 2009; Virtanen et al., 2009; Zingaretti et al., 2009). These studies indicate 
that BAT activity is inversely correlated with the severity of the metabolic syndrome and that 
BAT is a major contributor to maintain a lean phenotype. Thus, intervention to increase BAT 
activity and/or mass is a viable strategy to treat obesity. 
 Canonical activation of the Jak/Stat pathway involves cytokine and growth factors 
binding to their cell surface receptors resulting in activation of one or several Jak kinases, 
which tyrosine phosphorylate specific residues in the cytoplasmic domains of the receptors. 
Tyrosine phosphorylated receptors provide docking sites for the Stats through their SH2 
domains. The activated Jaks also phosphorylate tyrosine on one or several Stats (Raz et al., 
1994; Stark et al., 1998). Tyrosine phosphorylated Stats form homodimers or heterodimers, 
translocate to the nucleus, and bind to regulatory elements in the promoters of cytokine-
stimulated early response genes (Decker et al., 1991; Pearse et al., 1991). Activation of the 
Jak kinase Tyk2 leads to tyrosine phosphorylation of Stat3 in response to different cytokines 
including type one interferons, IL-12 and IL-23. 
          Up to now, no evidence existed that Tyk2, a Jak kinase family member, has any role in 
the pathogenesis of obesity. In this study we make the novel observations that expression of 
Tyk2 is required for differentiation of Myf5+ brown adipocytes, and that Tyk2-/- mice become 
obese with age. Furthermore, Tyk2 levels are regulated by diet in mice, and  Tyk2 levels are 
decreased in obese humans. Expression of constitutively active Stat3, (CAStat3) can restore 
BAT differentiation of Tyk2-/- preadipocytes and reverse the obese phenotype in Tyk2-/- 
mice. Moreover, rosiglitazone-induced stabilization of PRDM16 protein is absent in Stat3-/- 
brown preadipocytes under conditions, where there is no change in levels of PRDM16 RNA, 
suggesting a new mechanism of Stat3 action.The data in this proposal provide new evidence 
for the unanticipated role of Tyk2 and Stat3 in the regulation of BAT differentiation and 
energy balance 
 
Results 
We observed that Tyk2-/- mice weighed more than their wild type littermates. By 12 
months of age the Tyk2-/- animals were approximately 20 grams heavier than Tyk2+/+ mice 
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(Fig. 1A). However, increased weights were observed as early as 12-16 weeks of age on 
normal chow diet (Fig. 1B). Tyk2-/- mice displayed abnormal glucose clearance suggestive 
of insulin resistance (Fig. 1C), as well as many other metabolic abnormalities, including 
elevated plasma insulin, cholesterol and free fatty acid levels (Supplemental Table. S1). 
Due to different susceptibilities of many mice strains to developing obesity, we examined 
whether Tyk2-/- mice on C57BL/6 and SV129 backgrounds became obese. Both Tyk2-/- 
mice on a C57BL/6 and SV129 background showed augmented weights on a normal chow 
diet. Furthermore, we observed the same metabolic defects in B10.Q/J mice that have a 
spontaneous mutation in Tyk2  (data not shown) (Shaw et al., 2003). A complete metabolic 
profile was obtained on 12 week old animals. When normalized to lean body mass (LBM) 
Tyk2-/- mice showed lower energy expenditure (Supplemental Fig. S1A and S1B) and 
produced 20% less heat (Supplemental Fig. S1C) during both, day and night cycles. No 
changes in food intake (Tyk2+/+ 13.4±5.5 g/48 hrs vs. Tyk2-/- 12.9±2.6 g/48 hrs) or physical 
activity were detected between Tyk2+/+ and Tyk2-/- mice. 
Tyk2 is ubiquitously expressed protein, whose concentrations vary between tissues 
(Strobl et al., 2011). The protein is abundant in BAT, WAT and spleen and is present in lower 
amounts in SKM and liver (Supplemental Fig. S2A). We examined, whether changes in 
energy expenditure might control the levels of Tyk2 expression in tissues. C57BL/6 Tyk2+/+ 
mice were placed on a high fat diet (HFD) for 12 weeks and Tyk2, Jak1 and Jak2  RNAs 
were analyzed in liver, skeletal muscle (SKM), BAT and WAT. Tyk2 RNA was selectively 
decreased in BAT and skeletal muscles by approximately 70% in mice on a HFD compared 
to those on normal chow (Fig. 1D), whereas Tyk2 RNA levels in WAT or liver were not 
changed. The expression of Tyk2 protein was also significantly decreased by 56% (p<0.05) 
in BAT from mice placed on a HFD (Supplemental Fig. S2B). Levels of Tyk2 protein in SKM 
from animals on a HFD were decreased 50% (p<0.05). Jak1 and Jak2 RNAs were not 
altered in mice placed on a HFD (Supplemental Fig. S2C and S2D). Similarly to mice fed a 
HFD, leptin deficient mice (ob/ob) also displayed decrease in Tyk2, but not Jak1 or Jak2 
RNA in BAT (Supplemental Fig. S2E). 
We also examined the levels of Tyk2 RNA from rectus abdominus muscle samples 
obtained from obese humans with or without type II diabetes (T2D). Tyk2 RNA levels were 
57% lower in the obese subjects and 52% lower in the obese-diabetic subjects, when 
compared with lean control subjects (Fig. 1E). There was no differences in Jak1 or Jak2 
expression between the groups (Supplemental Fig. S2F).  
Reduced energy expenditure in Tyk2-/- mice suggested additional abnormalities in 
BAT-specific gene expression in Tyk2-/- mice. Expression of uncoupling protein 1 (UCP1), 
PRDM16, and Cidea (cell death-inducing DFFA-like effector a) was diminished in BAT 
isolated from 16 week old Tyk2-/- mice compared with wild type animals (Fig. 1F). 
Additionally, Tyk2-/- mice showed a defect in the expression of β-oxidation enzymes AOX 
(acyl-CoA oxidase) and LCAD (long chain acyl-CoA dehydrogenase) in BAT (Supplemental 
Fig. S1D).  However, RNAs that are normally highly expressed in BAT like PPARγ and 
PGC1α were not different between Tyk2+/+ and Tyk2-/- animals. The protein levels 
corresponding to these RNAs were also decreased in BAT of Tyk2-/- mice (Fig. 1G). Defects 
in the morphology of BAT from Tyk2-/- animals were obvious by hematoxylin and eosin 
staining. Tyk2-/- BAT cells contained large unilocular fat droplets, whereas Tyk2+/+ BAT 
showed multilocular fat droplets (Fig. 1H). 
We also examined the mitochondrial morphology of BAT from Tyk2+/+ and Tyk2-/- 
mice using transmission electron microscopy. The mitochondria of Tyk2-/- BAT and skeletal 
muscle showed disorganized cristae, but no alterations in mitochondria morphology was 
observed in the heart (Supplemental Fig. S3A). 
Mitochondrial function and ultrastructure depend on the proper fusion of the outer and 
inner membranes (Zick et al., 2009). The fusion processes are governed by three large 
GTPases: mitofusin 1 (Mfn1), mitofusin 2 (Mfn2) and optic atrophy protein 1 (OPA1). Mfn1 
and Mfn2 are involved in early steps of outer membrane fusion, whereas OPA1 is associated 
with inner membrane fusion and cristae remodeling (Chen and Chan, 2010). Disorganization 
of mitochondrial cristae observed in BAT and skeletal muscles from Tyk2 deficient mice 
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correlated with decreased OPA1 expression in these tissues (Supplemental Fig. S3B). 
Reduced mRNA levels of OPA1 were not observed in the control tissues, such as WAT or 
liver. The expression levels of Mfn1 in SKM and Mfn2 in BAT were modestly changed 
(Supplemental Fig. S3C and S3D). It is notable that elevated expression of these RNAs is 
associated with an insulin-sensitive phenotype in humans (Lidell et al., 2011).  Since BAT 
and skeletal muscles originate from the same Myf5 positive progenitor cells, (Seale et al., 
2008), we conclude that Tyk2 kinase may be important at an early stage of development of 
these progenitors.  
To further confirm a functional defect in Tyk2-/- BAT, oxygen consumption assays 
were performed using isolated mitochondria from Tyk2+/+ or Tyk2-/- BAT (Fig. 1I). 
Compared with Tyk2+/+ mitochondria, oxygen consumption was decreased in Tyk2-/- 
mitochondria using pyruvate and malate as substrates for complex I activity and succinate for 
complex II activity. Addition of GDP, which inhibits the activity of UCP1, decreased O2 
consumption of Tyk2+/+, but not Tyk2-/- mitochondria. The addition of DNP (an uncoupler of 
OXPHOS) increased O2 consumption of Tyk2+/+ and Tyk2-/- mitochondria. The respiratory 
activities of Tyk2-/- mitochondria were comparable to those reported in BAT mitochondria 
from UCP1 deficient mice (Dlaskova et al., 2010).  
Since BAT plays a central role in nonshivering thermogenesis, which maintains body 
temperature during cold exposure, we examined body temperature and the induction of 
UCP1 in mice exposed to 40C for 12 hrs. There was a significant induction in UCP1 RNA in 
BAT in Tyk2+/+ but not in Tyk2-/- mice (Fig.1J). Body temperatures were also significantly 
lower in Tyk2-/- animals (Fig. 1K). The mechanisms for enhanced sensitivity to cold in Tyk2-
/- mice may be due to dysfunctional BAT, which controls nonshivering thermogenesis and/or 
from a defect in skeletal muscle that is responsible for shivering thermogenesis.   
Decrease in BAT-specific RNAs was also observed in in vitro differentiated brown 
preadipocytes isolated from the interscapular BAT of Tyk2-/- mice (Table 1). Tyk2-/- 
preadipocytes did not differentiate as indicated with Oil red O staining (Fig. 2A). Furthermore, 
Tyk2-/- preadipocytes were infected with retroviruses expressing Tyk2, constitutively active 
Stat3 (CAStat3) or the empty vector (MSCV) and subjected to in vitro differentiation (Tseng 
et al., 2004). Cells expressing Tyk2 or CAStat3, but not the control vector, became Oil red O 
positive (Fig. 2A). Levels of BAT-specific RNAs were completely restored by expressing 
CAStat3, and were partially restored by Tyk2 (Table 1). The explanation as to why the 
expression of wild type Tyk2 failed to completely restore BAT-specific RNAs is not clear. 
Since BAT and skeletal muscle share a common progenitor, and PRDM16 levels are 
diminished in Tyk2-/- preadipocytes (Seale et al., 2008), we analyzed expression of skeletal 
muscle-specific genes. The three muscle-selective  markers  MCK, MyoD and Myg were all 
elevated in Tyk2-/- compared with Tyk2+/+ preadipocytes (Table 1 lower panel). 
Interestingly, the expression of CAStat3 in Tyk2-/- preadipocytes was much less effective 
than Tyk2 in decreasing the levels of muscle-specific RNAs (Table 1). These results suggest 
that there are two different functions of Tyk2: one is to induce the expression of BAT-specific 
genes, which is effectively accomplished by the expression of Tyk2 or CAStat3. The other is 
the repression of skeletal muscle markers, which requires Tyk2 and is poorly restored by the 
expression of CAStat3. 
UCP1 and Cidea are expressed in BAT and their expression in brown adipocytes is 
regulated by DNA methylation and chromatin remodeling (Karamanlidis et al., 2007; 
Karamitri et al., 2009; Shore et al., 2010). Using bisulphite sequencing we determined the 
methylation status of the CpGs in the promoters of UCP1 and Cidea genes. We observed 
hypermethylation of DNA within these promoters in Tyk2-/- preadipocytes (Supplemental 
Fig. S4A), especially at the regions containing the C/EBPβ binding sites, which are crucial 
for the expression of UCP1 and Cidea (red frames in Supplemental Fig. S4A). 
Furthermore, the abundance of trimethylated histone H3 at lysine 4 (H3K4me3), which is a 
mark of transcriptionally active chromatin was lower in the UCP1 and Cidea promoters in 
Tyk2-/- differentiated brown adipocytes (Supplemental Fig. S4B and S4C). As an internal 
control, we examined the abundance of H3K4me3 at the p16 promoter, which was the same 
in Tyk2+/+ and Tyk2-/- preadipocytes (Supplemental Fig. S4D). p16 expression and 
methylation are not affected by BAT differentiation. 
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Since CAStat3 rescues differentiation in Tyk2-/- preadipocytes, we examined whether 
Stat3 was required for brown adipocyte differentiation. Stable preadipocyte lines were 
created using shRNA directed against Stat3 or a scrambled control (SCR). Western blot 
analysis showed complete loss of Stat3 protein (Fig. 2B), which correlated with decreases in 
BAT-specific gene expression (UCP1, Cidea) but not in adipogenic markers (PPARγ and 
aP2) (Fig. 2C). The normal levels of PPARγ and aP2 in these cells is consistent with the 
observation that they display normal adipogenesis and become Oil red O positive (data not 
shown). 
PRDM16 and C/EBPβ control the conversion of myoblastic precursors to brown 
adipocytes and are sufficient to induce differentiation of fully functional brown adipocytes 
from nonadipogenic embryonic fibroblasts (Seale et al., 2008; Seale et al., 2007). Since 
PRDM16 is a master regulator of BAT development, we tested if its over expression could 
induce differentiation in Tyk2-/- preadipocytes. Tyk2-/- cells were infected with retroviruses 
expressing PRDM16 and/or C/EBPβ. PRDM16 expression increased the differentiation of 
brown adipocytes as demonstrated both by Oil red O staining (Fig. 3A) and gene expression 
(Table 2). Expression of C/EBPβ alone had no effect on differentiation of Tyk2-/- brown 
preadipocytes (Fig. 3A). However, a combination of both PRDM16 and C/EBPβ fully 
restored differentiation of Tyk2-/- preadipocytes to the level observed in Tyk2+/+ cells. 
Furthermore, immunoprecipitation of PRDM16 from these cells demonstrated that 
endogenous Stat3 formed a complex with PRDM16 (Fig. 3B). We have also detected the 
complex in cell extracts immunoprecipitated with Stat3 (Fig. 3C), as well as in adipocytes, 
which express endogenous levels of PRDM16 and Stat3 (Fig. 3D). We have not observed 
any changes in the association of PRDM16 and Stat3 in cells treated with rosiglitazone (data 
not shown).   
Treatment of preadipocytes with the PPARу agonist rosiglitazone stabilizes PRDM16 
protein (Ohno et al., 2012). Since PRDM16 intereacts with Stat3 and the expression of both 
is required for differentiation of brown adipocytes, we examined PRDM16 protein levels in 
Stat3+/+ and Stat3-/- preadipocytes incubated with or without rosiglitazone, while the cells 
were being differentiated (Fig. 3E). Basal levels of PRDM16 protein were very much 
decreased or absent in differentiated Stat3-/- adipocytes and rosiglitazone induction of 
PRDM16 was severely blunted. We also incubated cells with or without rosiglitazone under 
nondifferentiating conditions (Fig. 3F). Although basal levels of PRDM16 were similar in 
Stat3+/+ and Stat3-/- cells prior to differentiation, rosiglitazone did not increase the 
expression of PRDM16 in Stat3-/- cells. Furthermore, expression of PPARу was not altered 
in Stat3-/- preadipocytes.  
In contrast to levels of PRDM16 protein, as reported by Ohno et al, (Ohno et al., 
2012), levels of PRDM16 RNA were not significantly changed in Stat3+/+ or Stat3-/- brown 
adipocytes with or without exposure to rosiglitazone (Fig. 3G).  
To determine whether the metabolic syndrome in Tyk2-/- mice was due to a defect in 
BAT development, we examined a mouse containing a constitutively active Stat3 transgene, 
whose expression is activated by Cre recombinase (Mesaros and Barsh, 2008). CAStat3 
mice were crossed with Tyk2-/- mice (Tyk2-/-CAStat3). Tyk2-/-CAStat3 mice were then 
crossed with aP2 Cre/Tyk2-/- mice that express Cre recombinase in adipose tissue to 
generate aP2-Cre/Tyk2-/-CAStat3 mice (Imai et al., 2001). Consistent with the results of 
Mesaros et al (Mesaros and Barsh, 2008) the transgene was expressed at physiological 
levels (data not shown). All experiments were performed using Tyk2-/- CAStat3 (controls-
CTR) and animals with the activated transgene aP2-Cre/Tyk2-/-CAStat3 (CAStat3), from the 
same litter. As previously reported, transgenes expressed under the control of the aP2 
promoter can be variably expressed in BAT, WAT or both tissues (Cho et al., 2009). 
Expression of the CAStat3 transgene preferentially in BAT of Tyk2-/- mice upregulated the 
levels of BAT-specific RNAs (UCP1, PRDM16, Cidea), which are severely diminished in 
Tyk2-/- animals (Fig. 4A). C/EBPβ, PPARγ and PPARα, which play important roles in BAT 
development, were also increased. The protein levels corresponding to these RNAs were 
also increased in BAT of CAStat3 mice (Fig. 4B). Furthermore, the altered BAT morphology 
depicted in (Fig. 1H) was restored by CAStat3 expression and resembled the tissue in wild 
type animals (Fig. 4C). Tyk2-/- mice expressing CAStat3 in BAT exhibited significantly 
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reduced body weight in comparison to control littermates (Fig. 4D). Moreover, CAStat3 mice 
had much lower plasma insulin levels than control animals, suggesting improved insulin 
sensitivity (Fig. 4E). The levels of insulin as well as body weight in the transgeneic mice were 
similar to wild type animals (data not shown).  
 
Discussion: 
The data in this report provide new evidence for the unanticipated role of Tyk2 and 
Stat3 in the regulation of Myf5+ BAT development and energy balance both in rodents and 
possibly humans. Tyk2-/- mice provide a new model to understand the role of BAT in 
pathogenesis of obesity. The observations that Tyk2 RNA in BAT and skeletal muscle is 
regulated by diet in rodents, and obese humans, who also have decreased levels of Tyk2 in 
skeletal muscle, offers new potential avenues for pharmacological and nutritional intervention 
to treat obesity. 
At the moment it is not clear whether the obese phenotype observed in Tyk2-/- mice 
is only due to impaired differentiation of BAT or whether a defect in SKM also contributes to 
obesity. Since we have used global Tyk2 knock out animals for these studies, it is also 
possible that the changes in overall metabolism   are a result of a multiple defects in more 
than one tissue. The fact that the CAStat3 transgene expressed in BAT of Tyk2-/- mice 
restores a normal phenotype argues that the actions of Stat3 do not required its activation in 
SKM. These results also argue against the concept that a defect in many tissues in the Tyk2-
/- mouse is required for the development of obesity. It remains to be determined, whether the 
actions of Tyk2 are mediated through Stat3 and/or another signaling pathway. 
White and brown adipocytes are derived from mesenchymal stem cells.  Interscapular 
BAT shares a common lineage with Myf5+ muscle progenitors, while brown adipocyte-like 
cells distributed within subcutaneous WAT and skeletal muscle have a different lineage 
(Schulz et al., 2011). Recent studies indicate that this model is more complex in that mixtures 
of Myf5+ and Myf5- cells are present in WAT (Sanchez-Gurmaches et al., 2012).  
Differentiation of Myf5+ progenitors into brown preadipocytes requires the expression of 
PRDM16. Our results suggest that Tyk2 and Stat3 are required for the progression of 
differentiation-incompetent preadipocytes to committed differentiation-competent brown 
preadipocytes such that PRDM16, C/EBPβ, Stat3, and other TFs can induce differentiation. It  
remains to be determined, whether Tyk2 and Stat3 directly or indirectly mediate the 
expression of BAT-selective RNAs. The fact that the DNA in the promoters of UCP1 and 
Cidea are hypermethylated in Tyk2-/- preadipocytes and markers of  the abundance of 
trimethylated histone H3 at lysine 4 (H3K4me3) are decreased  is consistent with an effect of 
Tyk2 on chromatin modeling.   
This leads us to speculate that the role of Tyk2 in differentiation of BAT is to directly 
or indirectly facilitate chromatin remodeling and accessability. A nuclear-localized pool of the 
related kinase Jak2 phosphorylates histone H3 (Dawson M.A., 2010). It is notable that Tyk2 
also localizes to the nucleus (Ragimbeau et al., 2001).  It is thus possible that the actions of 
Tyk2 are unrelated to those of Stat3 and classic cytokine activation of the Jak/Stat pathway. 
An alternative or additional role of Tyk2 might be to modify Stat3 such that in combination 
with PRDM16 and C/EBPβ it induces the expression of BAT-specific genes. Under this 
scenario, CAStat3 would be modified in the absence of Tyk2 such that it can induce 
differentiation of Tyk2-/- preadipocytes. Tyrosine phosphorylation of Stat3 probably is not the 
modification of this protein mediated by Tyk2 because both basal levels of tyrosine 
phosphorylated Stat3 in preadipocytes, and tyrosine phosphorylated Stat3 during 
differentiation are not different between Tyk2-/- and Tyk2+/+ cells (data not shown). 
Acetylation and  methylation  have been reported to modify Stat3 and contribute to the 
effects of Stat3 in gluconeogenesis (Nie et al., 2009; Yang et al., 2010).  
In contrast to the ability of CAStat3 to induce BAT-specific gene expression, CAStat3 
does not substitute for wild type Tyk2 in repressing the expression of muscle specific genes 
during differentiation of preadipocytes (Table 1). Disrupted expression of Stat3 in Tyk2+/+ 
preadipocytes diminished BAT-selective gene expression, indicates that this transcription 
factor plays an essential role in two stages of BAT development: the progression of 
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differentiation-incompetent to differentiation-competent preadipocytes, and the development 
of differentiation-competent adipocytes into mature brown adipocytes. At the moment it is not 
clear whether progression from differentiation-competent to mature brown adipocytes 
requires Tyk2.  
     The expression of CAStat3 in BAT of Tyk2-/- mice is consistent with the results in cell 
culture models. However, the aP2 Cre promoter used to express CAStat3 in Tyk2-/- mice  is 
also expressed in macrophages and brain, leaving the possibility that these tissues may also 
be involved in the obese phenotype (Kloting et al., 2008; Mao et al., 1993; Urs et al., 
2006). We have not detected expression of CAStat3 in macrophages indicating that they do 
not contribute to the actions of CAStat3 in preventing the development of obesity. We have 
not examined, whether CAStat3 mice express the transgene in brain. However, if CAStat3 
expression in the brain is contributing to the prevention of obesity, then we would expect to 
see changes in the metabolic profile of mice that express CAStat3 only in WAT and brain. 
The limited numbers of animals that express CAStat3 only in WAT that have been examined, 
display the same phenotype as Tyk2-/- mice. These results suggest that it is unlikely that 
expression of CAStat3 in the brain is contributing to the obesity observed in Tyk2-/- mice.   
    The observation that rosiglitazone-induced stabilization of PRDM16 protein is absent in 
Stat3-/- brown preadipocytes under conditions, where there is no change in levels of 
PRDM16 RNA suggests a new mechanism of Stat3 action. We have examined whether the 
expression of Stat3 controls the rate of degradation of PRDM16 by treating cells with 
cycloheximide (Ohno et al., 2012). There were no changes in half life of PRDM16 protein in 
Stat3-/- compared to Stat3+/+ preadipocytes, suggesting that in these cells the rate of 
translation of PRDM16 is being influenced by the presence  of Stat3. However, these results 
are ambiguous because the endogenous levels of PRDM16 are very low in Stat3-/- cells 
which makes it very difficult to analyze rates of decay of the protein. Stat3 may directly 
stabilize PRDM16 protein, presumably by their direct interaction (Fig. 3B, 3C and 3D). 
Alternatively, Stat3 may regulate the expression of RNAs that encode proteins involved in 
stability of PRDM16. Since PRDM16 is destabilized through the ubiquitin (Ub)-proteasome 
targeting system, this complex is also a potential target of Stat3. In renal cancer cells Stat3 
has been reported to bind and stabilize HIF1a but the physiological consequences of this 
interaction need to be clarified (Jung et al., 2005).  
Further characterization of the mechanisms by which Tyk2 and Stat3 regulate brown 
fat development in animal models and a better understanding of the signaling cascade 
governed by these proteins will help design screens for new targets to treat obesity and the 
metabolic syndrome. 
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Materials and methods: 
 
Reagents and antibodies 
 
All chemicals and reagents were purchased from Sigma-Aldrich or indicated otherwise. For 
western blot analysis, antibodies were purchased from Cell Signaling (mouse monoclonal 
Stat3 and rabbit polyclonal PPARу), Sigma-Aldrich (mouse monoclonal alpha-tubulin), 
Abcam (rabbit polyclonal PPARα and rabbit polyclonal UCP1), Life Span Biosciences (rabbit 
polyclonal Cidea). Tyk2 antisera were a kind gift of Dr. Birgit Strobl (University of Veterinary 
Medicine, Vienna, Austria). PRDM16-specific rabbit polyclonal antibodies were a kind gift of 
Dr. Patrick Seale (University of Pennsylvania, School of Medicine, Philadelphia, USA). 
 
Subjects 
 
Ten lean controls (4 men, 6 women; average age: 45.3  2.8), 15 obese (3 men, 12 women; 
average age: 36  2.1) and 12 obese type-2 diabetic (8 men, 4 women; average age: 49.3  
1.4) individuals participated in this study. Obese and obese type-2 diabetic patients were 
undergoing laparoscopically performed adjustable gastric banding surgery, as previously 
described (O'Brien et al., 2005). None of the patients were under thiazolidinedione but some 
of them under insulin treatment. Lean patients were undergoing general abdominal surgical 
procedures unrelated to obesity or type-2 diabetes. The subject details have been published 
previously (Russell et al., 2012). Written informed consent was obtained from all subjects. 
This study was approved by the Deakin University Human Ethics Research Committee, The 
Avenue Hospital and Cabrini Hospital. Muscle samples (about 200 mg) were obtained from 
the rectus abdominus in the fasted state (8-18 hrs). All participants were under general 
anaesthesia, predominantly via short-acting propofol and maintained by a fentanyl, 
rocuronium and volatile anaesthesia mixture.  Following collection, which was performed 30 
min after the operation had started, surgical samples were immediately frozen in liquid 
nitrogen. 
Statistical analysis was performed using SPSS version 15.0. A one-way analysis of variance 
(ANOVA) followed by LSD or Dunnett's T3 post-hoc test was used (where equal variances 
were not assumed) to determine the significance of differences between groups. Significance 
was set at p<0.05. 
 
Animals 
 
All the mice were bred and maintained in the MCV/VCU animal facility according to 
Institutional Animal Care and Use Committee (IACUC) regulations. Male mice were used for 
these studies. Tyk2 deficient mice (C57BL/6) were kindly provided by Dr. Ana Gamero 
(Temple University School of Medicine, Philadelphia, USA). Tyk2-/- (SV129) were generated 
by Dr. Kazuya Shimoda and colleagues (Kyushu University, Fukuoka, Japan) (Shimoda et al., 
2000). Mice carrying a transgene encoding a constitutively active form of the Stat3 protein 
(CAStat3) including an upstream loxP- flanked stop sequence in the ubiquitously expressed 
Rosa26 locus were a kind gift of Dr. Klaus Rajewsky (Harvard Medical School, Boston, USA) 
(Mesaros and Barsh, 2008) . The Tyk2-/- mice expressing the constitutively active Stat3 only 
in BAT (brown adipose tissue) or WAT (white adipose tissue) were obtained by crossing 
CAStat3 transgenic animals with mice expressing the Cre recombinase under control of the 
aP2 promoter, allowing adipocyte-specific expression of Cre. Both transgenic lines (CAStat3 
and aP2-Cre) were bred with Tyk2-/- mice and then intercrossed. Only animals from the 
same mixed background strain generation were compared. The specificity of transgene 
expression was confirmed by qPCR. Mice carrying floxed alleles of Stat3 were kindly 
provided by Dr. Valeria Poli (University of Turin, Italy).   
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Cell Culture 
 
Interscapular brown adipose tissue was isolated from newborn Tyk2+/+ and Tyk2-/- mice, 
minced and subjected to collagenase A digestion (1.5 mg/ml in isolation buffer containing 
123 mM NaCl, 5 mM KCl, 1.3 mM CaCl2, 5 mM glucose, 100 mM HEPES and 4% BSA) for 
40 min at 37oC (Fasshauer et al., 2000). Collected cells were centrifuged at 1500 rpm at 
room temperature for 5 min and then resuspended in 1 ml of primary culture medium 
(Dulbecco’s modified Eagle medium, 4500 mg/L glucose Gibco, Carlsbad, CA) containing 
20% FBS, 20 mM HEPES and 1% penicillin-streptomycin), transferred into 12 well plates and 
grown in a humidified atmosphere of 5% CO2 and 95% O2 at 37°C. After 3 days of culture, 
cells were immortalized by infection with puromycin resistance retroviral vector pBabe 
encoding SV40 Large T antigen. 24 hrs after infection cells were split into 10 cm dishes and 
maintained in primary culture media for the next 24 hrs and then subjected to selection with 
puromycin at a concentration of 2 μg/ml in DMEM with 20% FBS for one week. 
For differentiation, brown preadipocytes were grown to 100% confluence in the differentiation 
medium: DMEM containing 4500 mg/L glucose, 10% FBS, 20 nM insulin and 1 nM 
triiodothyronine. Fully confluent cells were incubated for 48 h in differentiation medium 
supplemented with 0.5 mM isobutylmethylxanthine (IMBX), 0.5 μM dexamethasone and 
0.125 mM indomethacin (induction medium). After 48 hrs of induction, cells were maintained 
in differentiation medium for 5 days.  
 
Constructs and viral transductions 
 
293T cells, used as packaging cells, were grown in complete DMEM medium containing 10% 
FBS and 1% penicillin-streptomycin. Cells were transfected in 10 cm dishes using Fugene 
reagent (Roche Diagnostics, Indianapolis, IN) according to the manufacturer’s instructions.  
The virus-containing medium was collected 48 hrs after transfection, centrifuged for 10 min 
at 500 x g and filtered through 0.45 μm filter. Viral supernatants were added to the cells for 
12 hrs in the presence of Polybrene (8 μg/ml polybrene, Chemicon Int., Temecula,CA), then 
diluted twice with the fresh medium. The next day the viral supernatant was removed and 
replaced by fresh medium. 
Retroviral vectors to express Tyk2, CAStat3, PRDM16 and C/EBPβ have been previously 
described (Potla et al., 2006). Lentiviral vector expressing shRNA targeting Stat3 (pFLRu-
shtat3-YFP) and helper vectors (CMV-VSV-G and pHR’8.2deltaR) were a kind gift of Dr. 
Barry Sleckman (Washington University, School of Medicine, St. Louis, USA). Retroviral 
vector expressing Cre recombinase was kindly provided by Dr. Michael David (University of 
California, San Diego, USA). 
 
Dietary studies 
 
Five week old mice were housed four or five per cage and maintained on a fixed 12 hrs 
light/dark cycle. The animals were fed regular chow diet (Teklad F6 S664, Harlan Tekland, 
Madison, WT) or high-fat diet (D12330, Research Diets, New Brunswick, NJ). The chow diet 
contained 27% kcal protein, 17% kcal fat and 57% kcal carbohydrate. The high-fat diet 
contained 20% kcal protein, 60% kcal fat and 20% kcal carbohydrate. The mice were kept on 
the diets for 12 weeks. They had free access to water and food. 
 
Glucose tolerance test (GTT)  
 
Mice were fasted overnight (16 hrs) and then 2 mg/g glucose was injected intraperitoneally. 
Blood glucose levels were measured using a One-Touch Ultra glucometer (LifeScan, Milpitas, 
CA) at 0, 15, 30, 60 and 120 min after glucose administration. 
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Biochemical analysis 
 
Mice were fasted overnight (16 hrs). Blood samples were collected performing heart 
punctures. Plasma samples were obtained by centrifuging blood in Microtainer plasma 
separator tubes (Becton Dickinson, Frankiln Lakes, NJ). Plasma was assayed for insulin 
using an Ultra sensitive mouse insulin ELISA kit (Crystal Chem Inc, Downers Grove, IL). The 
measurements of blood cholesterol, β-hydroxybutyrate, FFA and triglycerides were 
performed by the Cincinnati Mouse Metabolic Phenotyping Center (MMPC). 
 
 
Mitochondrial preparation 
 
Brown adipose tissue mitochondria were prepared as described previously (Shabalina et al., 
2004). Briefly, four Tyk2+/+ and/or Tyk2-/- mice were sacrificed for each experiment. The 
interscapular brown adipose tissue depots were dissected out, cleaned from white adipose 
tissue and pooled in ice-cold isolation buffer (250 mM sucrose, 10 mM Tris-HCl, 1mM EDTA, 
0.2% defatted BSA). The tissue was kept at 4°C throughout the isolation process. The tissue 
was minced with scissors, homogenized in a glass homogenizer with Teflon pestle and 
centrifuged 8500 x g for 10 min. The supernatant containing fat layer was discarded. The 
pellet was resuspended in isolation buffer and centrifuged at 500 x g for 10 min. The 
resulting supernatant was transferred to a clean tube and centrifuged again at 8500 x g for 
10 min. The mitochondrial pellet was resuspended in KME buffer pH 7.4 (100 mM KCl, 50 
mM MOPS, 0.5 mM EGTA) and used within 4 hrs after isolation. The protein concentration 
was measured using the Lowry method (with BSA as a standard and sodium deoxycholate 
as a detergent) (Lowry et al., 1951).      
 
Oxygen consumption  
 
Oxygen consumption was measured using a Clark-type oxygen electrode (Strathkelvin 
Instruments, North Lanarkshire, UK) at 30 °C in respiration buffer at pH 7.4 (100 mM KCl, 50 
mM MOPS, 1 mM EGTA, 5 mM KH2PO4, 0.1% defatted BSA). The mitochondrial suspension 
was continuously stirred in the chambers using magnetic stirrers. Oxygen consumption rates 
were measures in the presence of the substrate of interest: for complex I (5 mM pyruvate 
plus 5 mM malate), for complex II (20 mM succinate with 7.5 μM rotenone). Subsequently, 1 
mM GDP and 0.2 mM dinitrophenol (DNP) were added.    
 
Measurement of energy expenditure by indirect calorimetry 
 
Metabolic rates were measured by indirect calorimetry in Tyk2+/+ and Tyk2-/- mice  by using 
an 8-chamber open-circuit Oxymax system (CLAMS, Columbus Instruments,Columbus, OH) 
at  Mouse Metabolic Phenotyping Center in the Case Western Reserve University (Cleveland, 
Ohio). Briefly, mice were individually housed in acrylic calorimeter chambers through which 
air of known O2 concentration was passed at a constant flow rate. The system automatically 
withdrew gas samples from each chamber hourly for 24 h. The system then calculated the 
volume of O2 consumed (VO2) and CO2 generated (VCO2) for each mouse in 1 h normalized 
by lean body mass. Body composition of unanesthetized mice was measured by quantitative 
magnetic resonance imaging using EchoMRI (Echo Medical Systems, Houston, TX) as 
previously described (Lo et al., 2008). The RQ, ratio of the VCO2 to VO2, was calculated. 
Heat expenditures were measured throughout the study in light and dark cycles and under 
fed and fasting conditions and represented in kcal/g/day. Mice were maintained at 25°C and 
had free access to water under all conditions. 
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Histology 
 
Brown adipose tissues were fixed in 10% formalin and were paraffin-embedded. Multiple 
sections were prepared and stained with hematoxylin and eosin (H&E) at the Pathology 
Research Service Facility (VCU Medical Center, Richmond, VA). 
 
Electron microscopy  
 
Brown adipose tissue, skeletal muscle and heart were fixed in 2% paraformaldehyde- 2% 
glutaraldehyde in 0.1 M cacodylate buffer. The tissue samples were processed and analyzed 
at the Microscopy Core Facility at the Department of Anatomy and Neurobiology (VCU 
Medical Center, Richmond, VA). 
 
 
Oil red O staining  
 
The Oil red O staining protocol was used to test for lipid accumulation in fully differentiated 
cells. Plates with cells were rinsed once with PBS and then fixed with buffered formalin for 1 
hr at room temperature. Fresh Oil red O working solution was prepared by adding 6 ml of the 
stock solution (0.5 g Oil red O in 100 ml of 2-propanol) to 4 ml of dH2O, mixed and filtered 
through Whatman filter paper. Following fixation the cells were incubated for 1hr at room 
temperature with Oil red O stain. Then plates were carefully rinsed several times with dH2O 
and air-dried before collecting images under the inverted microscope.  
 
RNA extraction and real-time qPCR 
 
Total RNA was isolated with TRI Reagent (Molecular Research, Cincinnati, OH), according 
to the manufacturer’s instructions. Isolated RNA samples were treated with DNase (Promega, 
Madison, WI), cDNA was synthesized from 2 μg of RNA with the Tetro cDNA Synthesis Kit 
(Bioline, Taunton, MA), real-time qPCR was performed using SensiMix SYBR and 
Fluorescein Kit (Bioline, Taunton, MA) according to manufacturer’s instruction. All the 
samples were assayed in duplicates and analyzed using a CFX96 Real-Time PCR Detection 
System (Bio-Rad, Hercules, CA). Table S2 contains a full list of the primer sequences. 
Primer for Tyk2, Jak1, Jak2, OPA1, Mfn1 and Mfn2 were purchased from SuperArray 
(Qiagen SABioscience, Frederick, MD). 
 
Western blot analysis 
 
Cells / tissues were lysed in ice-cold extraction buffer (20 mM HEPES, 300 mM NaCl, 10 mM 
KCl, 1 mM MgCl2, 20% glycerol, 1% Triton X-100) with added protease and phosphatase 
inhibitor cocktails (Roche, Indianapolis, IN) for 30 min at 4°C. After lysis, cell debris was 
removed from the lysates by centrifugation at 20,000 x g for 20 min at 4°C. The protein 
concentration in the supernatants was determined using a Bio-Rad protein assay (Bio-Rad, 
Hercules, CA). Equal amounts of protein were mixed 1:1 with 2X Laemmli sample buffer 
containing 1 mM β-mercaptoethanol, separated using SDS-PAGE electrophoresis and 
transferred to Immobilon-P PVDF membranes. Membranes were blocked for 1 h at room 
temperature with 5% non-fat dry milk and then incubated overnight at 4oC with the indicated 
primary antibodies. Amersham ECL Plus Western Blotting Detection Reagent (GE 
Healthcare Life Sciences, Piscataway, NJ) was used for chemiluminescent detection. Image 
J software was used for quantifying the intensity of signals.  
 
Immunoprecipitation 
 
Whole cell extracts were incubated overnight at 4°C with PRDM16 antibodies or Stat3 rabbit 
antisera plus agarose beads or control IgG plus agarose beads in an IP buffer pH 7.4 (150 
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mM NaCl, 50mM Tris-HCl, 1% Triton, 1 mM EDTA with added protease and phosphatase 
inhibitor cocktails (Roche, Indianapolis, IN). Immunoprecipitates were washed five times with 
wash buffer (150 mM NaCl, 50mM Tris-HCl, 1% Triton, protease and phosphatase inhibitor 
cocktails), separated by SDS-PAGE and blotted with indicated antibodies.   
 
Bisulfite sequencing 
 
1.5 μg of genomic DNA was converted using EZ DNA methylation kit (Zymo Research, 
Orange, CA) according to the supplier’s instructions. The treated DNA was amplified by PCR 
using the bisulfite-specific primers listed in Table S3. The amplification conditions for the 830 
bp (Cidea promoter) and 730 bp (UCP1 promoter) DNA fragments were as follow: stage 1: 
95 oC/ 3 min/ 1 cycle; stage 2: 95 oC/ 1 min/ 55 oC/ 1 min/ 73 oC/ 1 min/ 40 cycles; stage 3: 73 
oC/ 5 min/ 1 cycle. PCR products were cloned into the pCR2.1-TOPO vector (Invitrogen, 
Carlsbad, CA), and 8-15 clones for each were picked and sequenced. 
 
Chromatin immunoprecipitation (ChIP) assay. 
 
Immortalized Tyk2+/+ and Tyk2-/- differentiated adipocytes were crosslinked with 1% 
formaldehyde for 10 min at 37oC and then washed with ice-cold PBS containing 125 mM 
glycine and 1 mM PMSF. Chromatin was sonicated and immunoprecipitated using specific 
antibodies exactly as described in the ChIP protocol provided by Upstate Inc. (Charlottesville, 
VA). The following antibodies were used: ChIPAb+ Trimethyl-Histone H3 (Lys4) from Milipore. 
The primers used in qPCR are listed in Table S4.  
 
Statistical analysis  
 
Results are presented as the mean ± SE. Statistical comparison was performed using two-
tailed Student’s t-test. While interpreting the data results a p-value less than 0.05 was 
considered statistically significant and annotated by *.   
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Figure Legends: 
 
Figure 1. Tyk2-/- mice develop metabolic abnormalities. 
A) Mice pictured at 12 months of age. B) Body weight of mice fed a normal chow diet at 16 
weeks of age (n = 5-8 mice per group. C) Glucose tolerance test in Tyk2+/+ and Tyk2-/- mice. 
16 week old mice were fasted for 16 h and injected intraperitoneally (IP) with 2 mg glucose/g 
body weight. Blood was collected from the tail vein and glucose was measured at the 
indicated times (n = 5-8 mice per group). D) Tyk2 RNA levels in BAT and skeletal muscle 
(SKM) are decreased in mice on a HFD. 5 week old mice were placed on a normal chow or 
HFD for 12 weeks and RNA was harvested from BAT, SKM, WAT and liver. RNAs 
corresponding to Tyk2, Jak1 and Jak2 were measured by qPCR (n = 5 mice per group). E) 
Tyk2 RNA levels are decreased in muscle samples from obese patients with or without T2D 
(n = 10-15 subjects per group). F) BAT-specific RNAs (UCP1, PRDM16 and Cidea) are 
decreased in interscapular BAT isolated from 16 week old Tyk2-/- mice. RNAs highly 
expressed in BAT (PPARγ and PGC1α) are not significantly changed in BAT isolated from 
Tyk2-/- mice (n=5-8 mice per group). G) The amounts of BAT-selective proteins are 
decreased in Tyk2-/- mice. Cell extracts from BAT of individual Tyk2+/+ and Tyk2-/- mice 
were analyzed by western blotting for the presence of PRDM16, PPARуPPAR, Cidea and 
UCP1 (n=5-8 mice per group). Intensity of signals were quantified by Image J software and 
presented in the table. All samples were normalized to tubulin. The values represent mean 
fold decrease ± SE over Tyk2+/+ set as 1. H) H&E staining of BAT from 16 week old Tyk2+/+ 
and Tyk2-/- mice (n = 4 mice per group). I) Oxygen consumption rates measured for isolated 
brown adipose tissue mitochondria are reduced in Tyk2-/- mice. Mitochondria were incubated 
under conditions described in the Materials and Methods section. Data represent 5 separate 
experiments. J) UCP1 RNA in BAT is elevated in Tyk2+/+ but not Tyk2-/- mice upon cold 
exposure. Mice were placed at 40C for 12 hrs prior to collection of RNA from BAT (n = 5 mice 
per group). K) Body temperatures measured with a rectal thermometer in Tyk2+/+ and Tyk2-
/- mice placed at 40 C (n = 5 mice per group). 
 
Figure 2. Expression of Tyk2 and Stat3 are required for differentiation of brown 
adipocytes. A) Expression of Tyk2 or CAStat3 in immortalized Tyk2-/- preadipocytes 
restores lipid accumulation.  Cell lines were subjected to in vitro differentiation and stained 
with working solution of Oil red O. B) Stat3 protein level in Tyk2+/+ preadipocytes infected 
with shRNA directed against Stat3 or a scrambled control (SCR). C) Amount of brown 
adipose tissue-specific (UCP1, Cidea) and adipogenic (PPARγ, aP2) RNAs in Stat3 shRNA 
or SCR control shRNA expressing adipocytes (n = 4 independent experiments). 
  
Table 1. Reduced gene expression in Tyk2 deficient adipocytes is restored by 
reconstitution with CAStat3 and partially with Tyk2. Total RNA was isolated from in vitro 
differentiated adipocytes and analyzed for selected RNA levels using qPCR. The values 
represent mean fold change ± SE over Tyk2+/+ set as 1, for n = 5 independent experiments. 
 
Figure 3. PRDM16 and Stat3 regulate differentiation of brown preadipocytes. A) Oil red 
O staining of immortalized brown adipocytes expressing indicated retroviral vectors 5 days 
after inducing adipocyte differentiation (n = 3 independent experiments). B) Stat3 
coimmunoprecipitates with PRDM16. Cell extracts prepared from differentiated Tyk2-/- 
adipocytes expressing  PRDM16 or PRDM16 and C/EBPβ were immunoprecipitated with 
either IgG  (lanes 1 and 3) or PRDM16 (lanes 2 and 4) antisera. The immunoblots were 
probed for either PRDM16 or Stat3. Endogenous Stat3 was detected in the complex with 
PRDM16 by western blotting. Input is shown in the lower panels. IB-immunoblot, IP-
immunoprecipitate (n = 3 independent experiments). C) The same cell extracts used in panel 
B were immunoprecipitated with either IgG or Stat3 antisera. The immunoblots were probed 
for either PRDM16 or Stat3. Input is shown in the lower panels (n = 3 independent 
experiments). D) Cell extracts from differentiated wild type brown adipocytes were 
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immunoprecipitated with either IgG or Stat3 antisera. The immunoblots were probed for 
either PRDM16 or Stat3. Input is shown in the lower panels (n = 2 independent experiments).  
E) Stat3-/- adipocytes are insensitive to rosiglitazone induced accumulation of PRDM16. Cell 
lines were generated from immortalized Floxed Stat3+/+ preadipocytes infected with a 
retrovirus expressing Cre recombinase or an empty vector control. Cell lines were 
differentiated in the presence or absence of rosiglitazone (1µM). Extracts were western 
blotted for the expression of PRDM16, Stat3 and tubulin as a control for protein loading (n = 
4 independent experiments). F) The same Stat3+/+ and Stat3-/- cell lines were incubated 
with or without rosiglitazone (1µM) for 4 days (non-differentiating conditions). Protein extracts 
western blotted for the expression of PRDM16, Stat3 and tubulin as a control for protein 
loading (n = 3 independent experiments) G) Stat3 expression does not affect cellular levels 
of PRDM16 RNA.  Cells were exposed to rosiglitazone as described in C). RNA was 
harvested and PRDM16 transcripts were measured by qPCR (n = 4 independent 
experiments). 
 
Table 2. Reconstitution of brown adipose tissue-specific gene expression in Tyk2-/- 
preadipocytes through PRDM16 and C/EBPβ. Total RNA was isolated from in vitro 
differentiated adipocytes and analyzed for selected RNA levels. The values represent mean 
fold change ± SE over Tyk2+/+ set as 1, for n = 4 independent experiments.   
 
Figure 4. Expression of CAStat3 in BAT reverses obesity in Tyk2-/- mice. A) The BAT-
specific RNA levels (UCP1, PRDM16, Cidea) and highly expressed BAT RNA expression 
(PPARγ, C/EBPβ, PPARα) are restored in tissue from Tyk2-/- mice that express the CAStat3 
transgene. Total RNA was isolated from interscapular BAT of 12 week old mice (n = 6-8 mice 
per group). B) The amounts of BAT-enriched proteins are increased in CAStat3 mice. Cell 
extracts from BAT of individual CTR and CAStat3 mice were analyzed by western blotting for 
the presence of PRDM16, PPAR, PPARу, Cidea and UCP1 (n=6-8 mice per group). 
Intensity of signals were quantified by Image J software and presented in the table. All 
samples were normalized to tubulin. The values represent mean fold increase ± SE over 
CTR mice set as 1. C) H&E staining of interscapular BAT from 12 week old control (CTR) 
and CAStat3 expressing mice (n = 5 mice per group). D)  Body weight of 24 week old 
CAStat3 and control mice fed a regular chow diet (n = 10-12 mice per group). E) Fasted 
plasma insulin levels of 24 week old control and CAStat3 expressing mice (n = 10-12 mice 
per group). 
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Supplemental Figure Legends 
 
Table S1. Metabolic analysis of Tyk2+/+ and Tyk2-/- mice. The parameters were 
determined from plasma taken via heart puncture from mice fasted for 16 h (n = 3 mice per 
group).  
 
Figure S1. Analysis of energy expenditure. Energy expenditure was measured for 24 hrs 
in individually housed 12 week old Tyk2+/+ and Tyk2-/- mice (n = 6 mice per group). All 
measured parameters are normalized by lean body mass (LBM). Energy expenditure is 
reported as A) VO2 consumption, B) VCO2 production, C) heat production, D) RNA levels of 
-oxidation enzymes (LCAD and AOX) are decreased in BAT isolated from 20 week old 
Tyk2-/- mice (n=5-10 mice per group).  
 
Figure S2. Analysis of Tyk2, Jak1 and Jak2 mRNA and Tyk2 protein in tissues from 
Tyk2+/+ and Tyk2-/- mice subjected to high fat diet (HFD) and skeletal muscle form 
obese and lean humans. A) Tyk2 protein levels were analyzed by western blotting in BAT, 
SKM, sWAT (subcutaneous), vWAT (visceral), liver and spleen isolated from C57BL/6 mice 
(n = 3 mice per group). 5 week old C57BL/6 mice were placed on a normal chow or HFD for 
12 weeks. Tissue extracts and RNA were harvested from BAT, SKM, WAT and liver. B) Tyk2 
protein level is decreased in BAT in mice fed HFD (n = 6 mice per group). C) Jak1 RNA and 
D) Jak2 RNA were measured by qPCR (n = 5 mice per group). E) Tyk2, Jak1 and Jak2 
expression in BAT from 12 week old control (CTR) and ob/ob mice fed  with normal chow 
diet (n = 5 mice per group). F) Jak1 and Jak2 RNA levels in skeletal muscle obtained from 
lean controls and obese patients with or without diabetes (n = 10-15 subjects per group).   
 
Figure S3. Changes in mitochondrial morphology in BAT and skeletal muscle of  
Tyk2-/- mice. A) Representative electron microscopy micrographs from BAT, SKM and heart 
of Tyk2+/+ and Tyk2-/- mice (n = 6 mice per group). The expression level of B) OPA1, C) 
Mfn1 and D) Mfn2 in BAT, SKM, WAT and liver of 12-week-old Tyk2+/+ and Tyk2-/- mice (n 
= 6-8 mice per group).   
 
Figure S4. DNA methylation is decreased and accumulation of histone activation 
marks are increased in the UCP1 and Cidea promoters in Tyk2+/+ compared with 
Tyk2-/- adipocytes. A) Cidea and UCP1 promoters show increased methylation in Tyk2-/- 
cells. Bisulphite sequencing of CpGs was carried out after isolation of genomic DNA from 
Tyk2+/+ and Tyk2-/- preadipocytes. Black and white circles indicate methylated and 
unmethylated CpGs, respectively. The red frames indicate CpGs overlapping with C/EBPβ 
binding sites. The Cidea promoter contains 44 CpGs (-550 to +250b). The UCP1 promoter 
contains 30 CpGs (-500 to +200b). 
Chromatin immunoprecipitaion (ChIP) assays were performed using immortalized and in vitro 
differentiated Tyk2+/+ and Tyk2-/- adipocytes. Cross-linked chromatin was 
immunoprecipitated with antisera that recognizes H3K4me3 or nonspecific IgG. The 
immunoprecipitates were subjected to qPCR using primers corresponding to B) the UCP1 
promoter or C) the Cidea promoter. D) As a control to demonstrate that the decreased 
binding of H3K4me3 to these promoters in Tyk2-/- cells was not a global effect on all 
transcription units, we also measured binding of H3K4me3 to the p16 promoter which is not 
altered by the lack of Tyk2 expression. Data represent four independent experiments.   
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Table S2. Real-time qPCR primer sequences.  
 
Gene 
 
Primer sequence 
 
UCP1 
(F) 5’- CTGGGCTTAACGGGTCCTC -3’ 
(R) 5’- CTGGGCTAGGTAGTGCCAGTG -3’ 
 
PRDM16 
(F) 5’- CAGCACGGTGAAGCCATTC -3’ 
(R) 5’- GCGTGCATCCGCTTGTG -3’ 
 
Cidea 
(F) 5’- TGCTCTTCTGTATCGCCCAGT -3’ 
(R) 5’- GCCGTGTTAAGGAATCTGCTG -3’ 
 
Elovl3 
(F) 5’- TCCGCGTTCTCATGTAGGTCT -3’ 
(R) 5’- GGACCTGATGCAACCCTATGA -3’ 
 
PGC1α 
(F) 5’- CCCTGCCATTGTTAAGACC -3’ 
(R) 5’- TGCTGCTGTTCCTGTTTTC -3’ 
 
PPARα 
(F) 5’- GCGTACGGCAATGGCTTTAT -3’ 
(R) 5’- GAACGGCTTCCTCAGGTTCTT -3’ 
 
PPARγ 
(F) 5’- GTGCCAGTTTCGATCCGTAGA -3’ 
(R) 5’- GGCCAGCATCGTGTAGATGA -3’ 
 
C/EBPβ 
(F) 5’- AAGAGCCGCGACAAGGC -3’ 
(R) 5’- GTCAGCTCCAGCACCTTGTG -3’ 
 
AOX 
(F) 5’- AAGAGTTCATTCTCAACAGCCC -3’ 
(R) 5’- CTTGGACAGACTCTGAGCTGC -3’ 
 
LCAD 
(F) 5’- GCTGCCCTCCTCCCGATGTT -3’ 
(R) 5’- ATGTTTCTCTGCGATGTTGATG  -3 
 
aP2 
(F) 5’- ACACCGAGATTTCCTTCAAACTG -3’ 
(R) 5’- ACACCGAGATTTCCTTCAAACTG -3’ 
 
MCK 
(F) 5’- GCAAGCACCCCAAGTTTGA -3’ 
(R) 5’- ACCTGTGCCGCGCTTCT -3’ 
 
Myg 
(F) 5’- AGCGCAGGCTCAAGAAAGTGAATG -3’ 
(R) 5’CTGTAGGCGCTCAATGTACTGGAT -3’ 
 
MyoD 
(F) 5’- CGCCACTCCGGGACATAG -3’ 
(R) 5’- GAAGTCGTCTGCTGTCTCAAAGG -3’ 
 
18S rRNA 
(F) 5’- CCATCCAATCGGTAGTAGCG -3’ 
(R) 5’- GTAACCCGTTGAACCCCATT -3’ 
 
human Tyk2 
(F) 5’-GGGACCGTGGGCAGGAGCTA-3’ 
(R) 5’-GTGCGTGTGGGAGACCTGGC-3’ 
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human Jak1 
(F) 5’-ATTGGCGAGATCCCCTTGA-3’ 
(R) 5’-GCACCGGCTTTCATAGAATCTCT-3’ 
 
human Jak2 
(F) 5’-TGATTTTGTGCACGGATGGA-3’ 
(R) 5’-ACTGCCATCCCAAGACATTCTT-3’ 
 
human Cyclophilin A 
(F) 5’-CATCTGCACTGCCAAGACTGA -3’ 
(R) 5’-GCAAAGTGAAAGAAGGCATGAA- 3’ 
 
 
 
 
Table S3. Bisulfite-specific primer sequences.  
 
Promoter 
 
Primer sequence 
Cidea 
(F) 5’- GTTTAGTTATTAATGGGTGGTACTATT -3' 
(R) 5’- AAAACACTCCACTAAACACCTATAAC -3' 
 
UCP1 
(F) 5’- GAAAGGGATATTTAGAATTGAAAGGAG -3’ 
(R) 5’- CTACCAACAAACTAAAACTCCGAC -3’ 
 
 
 
 
Table S4. ChIP primer sequences. 
 
 
Promoter 
 
Primer sequence 
Cidea 
(F) 5’- GAGGTTCCTCCCGAAAAAGG -3’ 
(R) 5’- CAACAGAATGAGGGCACCC -3’ 
 
UCP1 
(F) 5’- GCACTCACGCCTCTCTGC -3’ 
(R) 5’- CCTCATCAATGTCACTAACTC -3’ 
 
p16 
(F) 5’- ACACTCCTTGCCTACCTGAA -3’ 
(R) 5’- CGAACTCGAGGAGAGCCATC -3’ 
 
 
 
 
 
 
 
 
 
 
 
 
